BioCentury | May 24, 2019
Product Development

Why quizartinib hiccup at ODAC shouldn’t derail Daiichi’s 2025 cancer drug goals

FDA's ODAC may have given the thumbs down to Daiichi’s quizartinib, but a stocked pipeline and another ongoing trial of the candidate suggest it’s more of a hiccup than a hurdle in the Japanese pharma’s...
BC Week In Review | Oct 27, 2017
Company News

Daiichi and MD Anderson partner to develop AML candidates

Daiichi Sankyo Co. Ltd. (Tokyo:4568) and the University of Texas MD Anderson Cancer Center (Houston, Texas) partnered to develop multiple therapies for acute myelogenous leukemia (AML). During the multiyear collaboration, MD Anderson is to conduct...
BC Extra | Dec 2, 2015
Company News

Management tracks

Opthalmology company Avalanche Biotechnologies Inc. (NASDAQ:AAVL) hired Paul Cleveland as CEO, effective Dec. 9. Cleveland was CEO at Celladon Corp. (NASDAQ:CLDN). Oncology and inflammation play Zai Laboratory Ltd. (Shanghai, China) named Qi Liu CMO. Liu...
BioCentury | Nov 9, 2015
Product Development

TRK or treat baskets

Loxo Oncology Inc. and Ignyta Inc. are each running Phase II trials of TRK inhibitors that could possibly lead to the first drug labels for cancers defined by molecular signature alone. If they succeed, it...
BC Week In Review | Jul 13, 2015
Company News

Daiichi Sankyo, Merck deal

Daiichi’s Plexxikon Inc. subsidiary and Merck partnered to evaluate Plexxikon’s PLX3397 and Merck’s melanoma drug Keytruda pembrolizumab in a Phase I/II trial in patients with advanced melanoma and solid tumors. The companies expect to begin...
BC Extra | Feb 20, 2015
Company News

Genentech's cobimetinib NDA gets Priority Review

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said FDA accepted for filing and granted Priority Review to an NDA for MEK inhibitor cobimetinib in combination with the marketed BRAF inhibitor Zelboraf vemurafenib to treat...
BC Extra | Dec 16, 2014
Company News

Genentech submits NDA for melanoma combo

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) submitted an NDA to FDA for the combination of the MEK inhibitor cobimetinib plus the BRAF inhibitor Zelboraf vemurafenib to treat metastatic melanoma in patients with BRAF...
BC Week In Review | Dec 15, 2014
Clinical News

PLX3397: Phase II start

Daiichi Sankyo’s Plexxikon Inc. subsidiary said PLX3397 will join the ongoing Phase II I-SPY 2 trial in 1H15 to treat patients with newly diagnosed, locally advanced breast cancer. I-SPY 2 is designed to rapidly and...
BC Extra | Dec 12, 2014
Clinical News

Plexxikon's PLX3397 to join I-SPY 2

Plexxikon Inc. said its PLX3397 will be included in the Phase II I-SPY 2 trial to treat patients with newly diagnosed, locally advanced breast cancer. PLX3397 will enter the ongoing trial, which is managed by...
BC Innovations | Nov 20, 2014
Cover Story

Tapping TOPK

Although targeting proteins involved in cell division is falling out of fashion in cancer research because of the difficulty of distinguishing between diseased and normal cells, several companies are still exploring enzymes that could be...
Items per page:
1 - 10 of 204
BioCentury | May 24, 2019
Product Development

Why quizartinib hiccup at ODAC shouldn’t derail Daiichi’s 2025 cancer drug goals

FDA's ODAC may have given the thumbs down to Daiichi’s quizartinib, but a stocked pipeline and another ongoing trial of the candidate suggest it’s more of a hiccup than a hurdle in the Japanese pharma’s...
BC Week In Review | Oct 27, 2017
Company News

Daiichi and MD Anderson partner to develop AML candidates

Daiichi Sankyo Co. Ltd. (Tokyo:4568) and the University of Texas MD Anderson Cancer Center (Houston, Texas) partnered to develop multiple therapies for acute myelogenous leukemia (AML). During the multiyear collaboration, MD Anderson is to conduct...
BC Extra | Dec 2, 2015
Company News

Management tracks

Opthalmology company Avalanche Biotechnologies Inc. (NASDAQ:AAVL) hired Paul Cleveland as CEO, effective Dec. 9. Cleveland was CEO at Celladon Corp. (NASDAQ:CLDN). Oncology and inflammation play Zai Laboratory Ltd. (Shanghai, China) named Qi Liu CMO. Liu...
BioCentury | Nov 9, 2015
Product Development

TRK or treat baskets

Loxo Oncology Inc. and Ignyta Inc. are each running Phase II trials of TRK inhibitors that could possibly lead to the first drug labels for cancers defined by molecular signature alone. If they succeed, it...
BC Week In Review | Jul 13, 2015
Company News

Daiichi Sankyo, Merck deal

Daiichi’s Plexxikon Inc. subsidiary and Merck partnered to evaluate Plexxikon’s PLX3397 and Merck’s melanoma drug Keytruda pembrolizumab in a Phase I/II trial in patients with advanced melanoma and solid tumors. The companies expect to begin...
BC Extra | Feb 20, 2015
Company News

Genentech's cobimetinib NDA gets Priority Review

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said FDA accepted for filing and granted Priority Review to an NDA for MEK inhibitor cobimetinib in combination with the marketed BRAF inhibitor Zelboraf vemurafenib to treat...
BC Extra | Dec 16, 2014
Company News

Genentech submits NDA for melanoma combo

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) submitted an NDA to FDA for the combination of the MEK inhibitor cobimetinib plus the BRAF inhibitor Zelboraf vemurafenib to treat metastatic melanoma in patients with BRAF...
BC Week In Review | Dec 15, 2014
Clinical News

PLX3397: Phase II start

Daiichi Sankyo’s Plexxikon Inc. subsidiary said PLX3397 will join the ongoing Phase II I-SPY 2 trial in 1H15 to treat patients with newly diagnosed, locally advanced breast cancer. I-SPY 2 is designed to rapidly and...
BC Extra | Dec 12, 2014
Clinical News

Plexxikon's PLX3397 to join I-SPY 2

Plexxikon Inc. said its PLX3397 will be included in the Phase II I-SPY 2 trial to treat patients with newly diagnosed, locally advanced breast cancer. PLX3397 will enter the ongoing trial, which is managed by...
BC Innovations | Nov 20, 2014
Cover Story

Tapping TOPK

Although targeting proteins involved in cell division is falling out of fashion in cancer research because of the difficulty of distinguishing between diseased and normal cells, several companies are still exploring enzymes that could be...
Items per page:
1 - 10 of 204